Terremoto – $108M Series C Degrader Platform

Summary Terremoto Biosciences has raised $108 million in a Series C financing to advance its covalent targeted protein degradation platform, including AKT1-targeting degraders into clinical development. What Happened The company secured $108M to support progression of its degrader pipeline, with a focus on AKT1, a…